Zhejiang Garden Bio-chemical High-tech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 20, 2022 at 04:05 am EDT
Share
Zhejiang Garden Bio-chemical High-tech Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 386.59 million compared to CNY 175.11 million a year ago. Revenue was CNY 386.59 million compared to CNY 175.11 million a year ago. Net income was CNY 151.15 million compared to CNY 91.61 million a year ago. Basic earnings per share from continuing operations was CNY 0.28 compared to CNY 0.17 a year ago. Diluted earnings per share from continuing operations was CNY 0.28 compared to CNY 0.17 a year ago.
Zhejiang Garden Biopharmaceutical Co Ltd, formerly Zhejiang Garden Bio-chemical High-tech Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of vitamin D3 upstream and downstream products. The Company's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The Company also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
ZHEJIANG GARDEN BIOPHARMACEUTICAL CO.,LTD. 
